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atrial ﬁbrillationto have microalbuminuria), and (vi) the capacity to read, comprehendDesigned for patients with mild to moderate chronic kidney disease
(CKD), dose modiﬁcations of the new oral anticoagulant (NOAC) agents
(dabigatran, rivaroxaban and apixaban) are available [1–4]; neverthe-
less, for those with unembellished or end-stage CKD, warfarin remains
the anticoagulant of choice, as there are no or very limited data for
these patientswith atrial ﬁbrillation (AF). Among subjects on hemodial-
ysis, warfarin has been used with acceptable risks of hemorrhage [5].
This risk factor-based approach for patients with non-valvular AF can
also be expressed as an acronym, CHA2DS2-VASc [congestive heart fail-
ure, hypertension, age ≥75 (doubled), diabetes mellitus, stroke (dou-
bled), vascular disease, ages 65–74, and sex category (female)] [6].
This system is grounded on a point system in which 2 points are
assigned for a history of stroke or transitory ischemic attack (TIA), or
age ≥75; and 1 point each is assigned for age 65–74 years, a history of
hypertension, diabetes, recent cardiac failure, vascular disease (myocar-
dial infarction, complex aortic plaque, and peripheral artery disease
[PAD], including prior revascularization, amputation due to PAD, or an-
giographic evidence of PAD, etc.), and female sex. Thus, this acronymex-
tends the CHADS2 scheme by considering additional stroke risk factors
that may inﬂuence a decision whether or not to anticoagulate.
Using a ‘real-world’ cohort of 3978 European subjects with AF from
the EuroHeart Survey, a new simple bleeding risk score, HAS-BLED (hy-
pertension, abnormal renal/liver function, stroke, bleeding history or
predisposition, labile INR, elderly (N65), drugs/alcohol concomitantly),
has been derived [7]. It would seem reasonable to use the HAS-BLED
score to assess bleeding risk in AF patients, whereby a score of ≥3 indi-
cates ‘high risk’, and some carefulness and regular review of the individ-
ual is needed following the initiation of antithrombotic therapy,
whether with vitamin K or aspirin.
This prospective, longitudinal study involved 296patientswith hyper-
tension and mild to moderate CKD, all of them having a history of symp-
tomatic paroxysmal AF. The study was conducted in agreement with the
Helsinki declaration and approved by the ethics committee of our institu-
tion. All patients signed the informed consent term before inclusion. This
studywas conducted at the Hospital e Clínica São Gonçalo, Rio de Janeiro,
Brazil. Patients were recruited from January 2012 till January 2015 from
theArrhythmias andArtiﬁcial Cardiac Pacing Service of the same hospital.
Enrolled patientsmet the following criteria: (i) essential hypertension for
N1 year, (ii) a physically normal heartwith an ejection fraction of N50% as
measured by echocardiography (Simpson'smethod), (iii) PAF (deﬁned as
AF episodes lasting b7 days with spontaneous termination) registered on
ECG or 24-h Holter monitoring, (iv) aged 18 to 80 years, (v) estimated
glomerular ﬁltration rate (eGFR) of N30 mL/min/1.73 m2, calculated
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [8] (patientswith eGFR N60mL/min/1.73m2were also requiredhttp://dx.doi.org/10.1016/j.ijcme.2016.11.009
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articland sign the informed consent form, and attend the study. Patients with
any of the following were excluded: (i) pregnancy; (ii) valvular disease
with signiﬁcant adverse sequelae; (iii) unstable angina, myocardial
infarction, transient ischemic attack or stroke within the preceding six
months; (iv) renovascular abnormalities; (v) psychiatric disease; (vi) al-
lergy to ionic contrastmedium; (vii) the inability to bemonitored clinical-
ly after the procedure; (viii) a known addiction to alcohol or drugs
that affects the intellect; (ix) a serious health condition that, in the
investigator's opinion, may have adversely affected the safety and/or efﬁ-
cacy of the participant or the study (e.g., abdominal aortic aneurysm, clin-
ically signiﬁcant peripheral vascular disease, diseases that might have
caused bleeding due to thrombocytopenia, hemophilia, or signiﬁcant ane-
mia); (x) congestive heart failure (symptoms of functional classes II to IV
heart failure on the New York Heart Association scale); (xi) a previous AF
ablation procedure; and (xii) treatment with amiodarone.
The subjects were divided into three groups according to their
NOACs use: dabigatran (n=131), rivaroxaban (n=114) and apixaban
(n= 51). All of themwere followed at least 18months to assess events
of bleeding. The primary endpoint of this study was a bleeding occur-
rence using NOACs since from their initiation. The results are expressed
as a mean and standard deviation for normally distributed data and as
median with interquartile range otherwise. Comparisons between
two-paired values were performed with the paired t-test in cases of a
Gaussian distribution and by theWilcoxon test otherwise. For normali-
ty of distribution, D'Agostino-Pearson test was used. Comparisons
between more than two-paired values were made by repeated-
measures analysis of variance or by Kruskal–Wallis analysis of variance
as appropriate, complemented by the post-hoc Tukey test. Categorical
variables were compared with Fisher's exact test. A two-tailed P-
value b 0.05 was used as a criterion for statistical signiﬁcance. Correla-
tions between two variables were performed by Pearson's chi-square
test in case of a Gaussian distribution and with the Spearman correla-
tion test otherwise. Kaplan–Meier analysis was performed to determine
the probability of success, estimated as the percentage of AF freedom.
Differences in arrhythmia-free survival were assessed with the log-
rank test. Cox regression analysis was applied to explore factors of AF
recurrences. All statistical analyses were performed using the program
Graphpad Prism v 7.0 (Graphpad Software, La Jolla, CA, USA).
The general features of the groups of patients are listed in Table 1.
The 296 patients were followed up during 18 months after the begin-
ning of the treatment. During the follow-up period, bleedingwas higher
in CKD patients with AF that was in use of rivaroxaban or apixaban in
comparison in those using dabigatran, hazard ratio [HR], 95% conﬁ-
dence interval [CI] and P value by Log-rank test, are showed in Fig. 1.
There was no difference related to bleeding in the comparison between
patients with CKD and AF in using of rivaroxaban vs. apixaban.
Dabigatran seems to be safer than rivaroxaban or apixaban in patients
with mild to moderate CKD and AF, reducing the risk of bleeding in
these patients, even though with a high HAS-BLED score. Although en-
couraging, our data are preliminary and need long-term validation in a
large population.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
General features of patients at baseline.
Parameters Dabigatran (D) Rivaroxaban (R) Apixaban (A) Overall P value
N 131 114 51 –
Age, years 67.9 ± 20.2⁎⁎ 57.8 ± 9.0 65.6 ± 10.1⁎ b0.0001
Body mass index, kg/m2 26.5 ± 5.0 27.1 ± 7.7 25.8 ± 9.3 0.5277
Male sex (%) 75 (57%) 62 (54%) 28 (55%) 0.8956
White ethnicity (%) 90 (69%) 81 (71%) 38 (75%) 0.7356
Atrial ﬁbrillation 131 (100%) 114 (100%) 51 (100%) 1.0000
Hypertension 131 (100%) 114 (100%) 51 (100%) 1.0000
Type 2 Diabetes Mellitus 60 (46%)⁎ 74 (65%) 26 (51%) 0.0101
Coronary artery disease 48 (37%) 35 (31%) 20 (39%) 0.4776
Stroke/transitory ischemic attack 31 (24%) 22 (19%) 7 (14%) 0.3085
Hyperlipidemia 72 (55%) 55 (48%) 29 (57%) 0.4651
Creatinine, mg/dL 1.30 ± 0.30 1.55 ± 0.60⁎⁎ 1.50 ± 0.22⁎ b0.0001
eGFR, mL/min/1.73 m2 56.7 ± 16.9 49.0 ± 17.5⁎ 48.0 ± 11.3⁎ 0.0002
Albumin:creatinine ratio, mg/g 80.0 ± 12.4⁎⁎ 86.2 ± 10.0⁎⁎ 72.3 ± 9.2⁎⁎ b0.0001
CKD stage 1 48 (37%) 45 (40%) 15 (29%) 0.4626
CKD stage 2 22 (17%) 16 (14%) 12 (24%) 0.3224
CKD stage 3 61 (46%) 53 (46%) 24 (47%) 0.9976
Antihypertensive
ACE-inhibitors/ARB 131 (100%) 114 (100%) 51 (100%) 1.0000
Diuretics 105 (80%) 88 (77%) 33 (65%) 0.0853
DHP Ca++ channel blockers 131 (100%) 114 (100%) 51 (100%) 1.0000
β-blockers 59 (45%) 60 (53%) 27 (53%) 0.4213
Mean 24-h ABPM, mm Hg
Systolic 126.0 ± 5.5 124.1 ± 8.2 124.5 ± 9.0 0.1105
Diastolic 81.7 ± 3.3 83.0 ± 17.2 82.8 ± 5.5 0.1529
CHA2DS2VASc score 6.1 ± 2.4 6.2 ± 2.9 5.7 ± 3.1 0.5458
HAS-BLED bleeding risk score 4.6 ± 2.1 5.2 ± 3.5 5.0 ± 3.3 0.2685
Values are expressed asmean± SDor %; ABPM, ambulatory blood pressuremeasurements; ACE, angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor blocker;
CHA2DS [2]-VASc score: cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)-vascular disease, ages 65–74 and sex category (female); INR= international normal-
ized ratio; OAC= oral anticoagulation, such as a vitamin K antagonist (VKA) adjusted to an intensity range of INR 2.0–3.0 (target 2.5).CKD, chronic kidney disease; DHP, dihydropyridine;
eGFR, estimated glomerular ﬁltration rate; HAS-BLED score: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (N65 years old),
drugs/alcohol concomitantly). Comparisons: Age, ⁎P = 0.0069 for R vs. A and ⁎⁎P b 0.0001 for D vs. R; Type 2 DiabetesMellitus, ⁎P = 0.0031 for D vs. R; Creatinine, ⁎P = 0.0149 for D
vs. A and ⁎⁎P b 0.0001 for D vs. R; eGFR, ⁎P = 0.0040 for D vs. A and ⁎P = 0.0008 for D vs. R; Albumin:creatinine ratio.
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